Generally, specific labeling is required to make sure that certain drugs, approved for use in animal feed or drinking water but not in liquid medicated feed, are not diverted to use in liquid feeds. Section 558.5(i) permits an applicant to seek a waiver from this requirement (§§ 558.5(h)), if there is evidence that it is unlikely a new animal drug would be used in the manufacture of a liquid medicated feed. If FDA receives one NADA per year seeking approval of the use of a liquid medicated feed and on average it takes 5 hours to prepare the request for waiver, the estimated paperwork burden is 5 hours.

Risk assessment of antimicrobial new animal drugs with regard to their microbiological effects on bacteria of human health concern (§§ 514.1(b)(6) and 514.8(c)(1)). FDA estimates that it receives ten risk assessments evaluating the microbial food safety of antimicrobial new animal drugs per year. FDA estimates that it takes on average 90 hours to put together the references and other materials in the format recommended by Guidance 152 and to summarize the hazards and associated risk(s). Thus, the total burden hours for preparing such risk assessments for submission to FDA is estimated to be 900 hours.

Form FDA 356V. FDA requests that an applicant fill out and send in with NADAs and supplemental NADAs, and requests for phased review of data to support NADAs, a Form FDA 356V to ensure efficient and accurate processing of information to support new animal drug approval. Over the past 5 fiscal years, FDA has received an average of 511 NADAs and supplements and 267 submissions of data to support NADAs. FDA estimates that it takes an average of 5 hours to read the instructions and fill out Form FDA 356V and organize the information that it will accompany. This results in a total of 3,890 burden hours.

Dated: December 5, 2007.

Jeffrey Shuren,
Assistant Commissioner for Policy.

[FR Doc. E7–23998 Filed 12–10–07; 8:45 am]

SUPPLEMENTARY INFORMATION:

I. Introduction

On September 27, 2007, the President signed into law FDAAA (Public Law 110–85). Section 104 of this statute created new section 736A of the act, which in addition to reauthorizing the Prescription Drug User Fee Act (PDUFA) for FYs 2008–2012, also authorized a new and separate user fee program for the advisory review of DTC prescription drug television advertisements. Participation in the program is voluntary. Sponsors can decide, at their own discretion, whether to seek FDA advisory review of DTC prescription drug television advertisements in advance of publicly broadcasting them. However, under the new law, if a sponsor decides to seek FDA advisory review of a DTC television advertisement, the sponsor must pay all applicable fees for that review under the DTC television user fee program.

In the Federal Register of October 25, 2007 (72 FR 60677), FDA issued a participation notice asking companies: (1) To notify FDA by November 26, 2007, if they intend to participate in the DTC television user fee program during FY 2008 and (2) if they do plan to participate, to identify the number of DTC television advertisements for prescription drug and biological products they plan to submit to CDER or CBER for advisory review during FY 2008. The information gathered in response to the participation notice is the basis for the fees this notice establishes that will be charged for each FY 2008 advisory review submission to FDA and to fund the operating reserve established under FDAAA.

II. Establishing the Advisory Review Fee and Operating Reserves

A. Basis for the Fee

The advisory review fee for FY 2008 will be $41,390 for each proposed DTC television advertisement voluntarily submitted for advisory review. The fee is based on the number of advertisements identified by all companies in response to the participation notice. The advisory review fees in FY 2008 are set at a level to generate target revenues of $6.25 million in the first year of the program. Individual fees have been determined by dividing the target revenue, established in the statute, by 151 (the number of television advertisements all...
companies have indicated in response to the participation notice that they intend to submit during FY 2008 for advisory review.

A participant who does not pay the fees on time as specified in the billing instructions included with the invoice will be assessed a fee of $62,085 because the statute establishes a 50 percent penalty for fees not paid on time. A participant who submits more advertisements for advisory review in FY 2008 than it has told FDA it plans to submit in response to the participation notice will be assessed for each additional submission a fee that is 50 percent greater than what they would have owed had they paid on time. A participant who intends to submit additional advertisements should notify Wayne Amchin (see FOR FURTHER INFORMATION CONTACT).

The target revenue figures will be adjusted annually for inflation and workload on a compounded basis in subsequent years. In each subsequent year of the program, FDA will issue a new notice of participation by June 1 of that year and a second notice by August 1 establishing the fees.

B. Operating Reserves

To establish operating reserves for the program, in the first year of their participation in the program, participants will be assessed a one-time participation fee that will be based on the number of submissions the participant identifies for that year. In this way, FDA will collect revenues of $6.25 million to be placed in reserve from which funds can be drawn if target revenues fluctuate downward in subsequent years. For companies who responded by November 26, 2007 (the date given in the participation notice), the operating reserve fee for each participant in FY 2008 will be an amount equal to the total amount assessed that company for the annual advisory review fees for FY 2008. For companies who responded to the participation notice by November 26, 2007, but do not pay the assessed operating reserve fee within the time period specified in the invoice, the operating reserve fee will be 50 percent higher than what they would have owed had they paid on time. For participants who join the program late in FY 2008 (i.e., those who did not notify FDA of their intent to participate by November 26, 2007), the operating reserve fee will be 50 percent higher than what they would have owed had they both notified FDA and paid on time.

Companies who join the program in subsequent fiscal years (FYs 2009–2012) will be assessed an amount for the operating reserve fee that will be at least as much as the amount they would have been assessed if they had joined the program at the start of FY 2008. Specifically, in subsequent years, the operating reserve fee for new participants will be the higher of: (1) The total amount of advisory review fees for all of the new participant’s proposed DTC television advertisements in the year the participant joins the program or (2) the total amount of advisory review fees that would have been assessed in FY 2008 for that number of proposed DTC television advertisements. This statutory fee structure limits the incentive for companies to join the program late, which could prevent the program from receiving sufficient funding in the initial year and place a disproportionate share of the cost of the program on those participants who join the program in its initial year of operation.

C. Effect of Inadequate Funding

The statute provides that if FDA fails to receive sufficient funding from companies by January 25, 2008, the program will not commence. Sufficient funding consists of a combined total amount of at least $11.25 million from advisory review fees and operating reserve fees. In the event that insufficient funding is received and the program does not commence, all collected fees will be refunded to the companies who paid.

III. Participating in the DTC Television User Fee Program

A. How Do Participating Companies Pay the User Fees for Advisory Review?

FDA will send invoices to each company for all submissions identified in response to the participation notice, and the advisory review fees and the operating reserve fees are due and payable on the date specified in the invoices. Participating companies should not send payment until after receipt of the invoice. FDA will also assign each participant a series of unique user fee ID numbers to correspond with the number of advisory reviews that participants have identified in response to the participation notice. For example, a company that has identified 10 advisory reviews will receive 10 unique user fee ID numbers in its invoice. Companies should assign one of its unique user fee ID numbers to each submission of a DTC television advertisement for FDA advisory review and reference this number in the submission cover letter and outer package. FDA will track this unique user fee ID number against the invoice to ensure that all applicable fees have been paid and that the company has an available balance of advisory reviews for each submission received by the FDA. A company’s advisory review submission will be considered incomplete and not accepted for review until all fees owed by the company for all advisory reviews and the operating reserve fee have been paid.

B. How Do I Send In DTC Television Advertisements for Advisory Review Under the DTC Television User Fee Program?

FDA intends to issue guidance for industry explaining how to submit proposed DTC television Advisory Review Request Packages for review by CDER and CBER under the DTC television user fee program. The guidance document will provide details on the contents, format, and procedures that FDA recommends be followed. The guidance will also explain how and where to submit advisory review request packages to start the DTC television user fee program performance clock. FDA will issue a Federal Register notice to announce the availability of this guidance. Prior to availability of the guidance, for questions about where or how to submit proposed DTC television advertisements for advisory review, what to include in your submission, the status of pending DTC television advertisements submitted for advisory review, or your remaining balance of advisory reviews under the DTC television user fee program, please contact Wayne Amchin (see FOR FURTHER INFORMATION CONTACT).

For questions about submissions to CBER (APLB), please contact Ele Ibarra-Pratt (see FOR FURTHER INFORMATION CONTACT).

C. What Happens if I Send In a DTC Television Advertisement for Advisory Review After October 1, 2007, but Before I’m Invoiced by FDA for My FY 2008 Fees?

The effective date for the assessment and collection of fees for DTC television advertisements under this program is October 1, 2007. Therefore, any proposed DTC television advertisement voluntarily submitted for advisory review in FY 2008 is subject to the fees established in this notice. FDA recognizes that, due to the timing of the enactment of FDAAA, the advisory review and operating reserve fees for FY 2008 were not established and billed before October 1, 2007, and that there will be a gap between the start of the fiscal year and the date that fees are due. FDA will contact companies who submit DTC television advertisements
DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Drug Safety and Risk Management Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Drug Safety and Risk Management Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA’s regulatory issues.

Date and Time: The meeting will be held on February 1, 2008, from 8 a.m. to 5 p.m.

Location: Hilton Washington DC/Silver Spring, Maryland Ballroom, 8727 Colesville Rd., Silver Spring, MD. The hotel phone number is 301-589-5200.

Contact Person: Theresa Watkins, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093), Rockville, MD 20857, 301-827-7001, FAX: 301-827-6776, e-mail: Theresa.Watkins@fda.hhs.gov, or FDA Advisory Committee Information Line, 1-800-822-0073 (301-443-6572 in the Washington, DC area), code 3014512535. Please call the Information Line for up-to-date information on this meeting. A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice. Therefore, you should always check the agency’s Web site and call the appropriate advisory committee hot line/phone line to learn about possible modifications before coming to the meeting.

Agenda: The committee will discuss the efficacy and safety of a new drug application (NDA) 22–054, INJETAFER (ferric carboxymaltose injection). Luitpold Pharmaceuticals Incorporated, used for the treatment of iron deficiency anemia in patients with postpartum hemorrhage or heavy uterine bleeding. FDA intends to make background material available to the public no later than 2 business days before the meeting. If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA’s Web site after the meeting. Background material is available at http://www.fda.gov/ohrms/dockets/ac/acmenu.htm, click on the year 2008 and scroll down to the appropriate advisory committee link.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before January 17, 2008. Oral presentations from the public will be scheduled between approximately 1 p.m. and 2 p.m. Those desiring to make formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before January 9, 2008. Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by January 10, 2008.

Persons attending FDA’s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets. FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Teresa Watkins at least 7 days in advance of the meeting.

FDA is committed to the orderly conduct of its advisory committee meetings. Please visit our Web site at http://www.fda.gov/oc/advisory/default.htm for procedures on public conduct during advisory committee meetings.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: December 5, 2007.

Jeffrey Shuren,
Assistant Commissioner for Policy.

ADDRESSES: Submit written submissions to (HFD–21), Food and Drug Administration, 5600 Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093), Rockville, MD 20857, 301–827–7001, FAX: 301–827–6776, e-mail: Theresa.Watkins@fda.hhs.gov

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Advisory Committees; Filing of Closed Meeting Reports

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that, as required by the Federal Advisory Committee Act, the agency has filed with the Library of Congress the annual reports of those FDA advisory committees that held closed meetings during fiscal year 2007.

ADDRESSES: Copies are available from the Dockets Management Branch (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, 301–827–8680.

FOR FURTHER INFORMATION CONTACT: Theresa L. Green, Committee Management Officer, Advisory Committee and Oversight Management Staff (HF–4), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1220.

SUPPLEMENTARY INFORMATION: Under section 10(d) of the Federal Advisory Committee Act (5 U.S.C. app. 1) and 21 CFR 14.60(d), FDA has filed with the Library of Congress the annual reports for the following FDA advisory committees that held closed meetings during the period October 1, 2006 through September 30, 2007:

Center for Biologics Evaluation and Research

Cellular, Tissue and Gene Therapies